摘要
目的观察吉西他滨联合顺铂对晚期非小细胞肺癌的临床疗效。方法回顾性分析91例晚期非小细胞肺癌患者的临床资料,随机分为对照组(45例)和观察组(46例),分别给予多西他赛联合顺铂和吉西他滨联合顺铂治疗。观察两组的治疗效果、无进展生存时间、不良反应发生情况,并进行比较。结果观察组总缓解率为45.65%,高于对照组的44.44%,但经比较差异无统计学意义(P>0.05);观察组和对照组无进展生存时间分别为(5.45±1.03)个月和(5.13±1.05)个月,差异无统计学意义(P>0.05);两组患者治疗过程中均出现一定的不良反应,包括血小板降低和白细胞降低等,其中除血小板降低发生率外(P<0.05),两组各项不良反应发生率经比较均无统计学意义。结论对晚期非小细胞肺癌采用吉西他滨联合顺铂化疗可以获得一定的临床疗效,具有一定的应用可行性。
Objective To observe the clinical efficacy of gemcitabine combined with cisplatin in the treatment of advanced non-small cell lung cancer. Methods Review the clinical data of patients with non small cell lung cancer were analyzed retrospectively in 91 cases of advanced in our hospital in December 2013 ~ 2015 year in October,were randomly divided into control group(45 cases) and observation group(46 cases),were given docetaxel combined with cisplatin and gemcitabine combined with cisplatin in the treatment of. The therapeutic effect,progression free survival time and adverse reactions were observed and compared between the two groups. Results The effect of two groups of patients were deter mined and compared to the total remission rate of observation group was 45. 65%,higher than 44. 44% in the control group,but there was no significant difference,( P> 0. 05);the progression free survival time statistics,observation group and control group respectively(5. 45 ± 1. 03) and(5. 13± 1. 05) months,there was no significant difference,( P > 0. 05);some adverse reactions were found in the two groups during treatment,including thrombocytopenia and leukopenia,which reduce the incidence rate of platelet in the observation group was significantly lower than the control group,the difference was statistically significant.( P < 0. 05),but the incidence of adverse reactions after there were no statistical differences( P > 0. 05). Conclusion Conclusion gemcitabine combined with cisplatin in the treatment of advanced non-small cell lung cancer has a certain clinical efficacy,and has certain application feasibility.
引文
[1]宋海平,王颂平,孙翠萍,等.多西他赛及吉西他滨分别联合顺铂治疗晚期非小细胞肺癌随机对照临床研究[J].中国癌症杂志,2008,18(7):531-534.
[2]胡兴胜,焦顺昌,张树才,等.培美曲塞及吉西他滨分别联合顺铂治疗初治晚期非小细胞肺癌安全性和有效性的随机对照研究[J].中国肺癌杂志,2012,15(10):569-575.
[3]何志高,严俊,陈国涵,等.长春瑞滨(NP)或吉西他滨(GP)联合顺铂治疗晚期非小细胞肺癌的成本效用研究[J].药学实践杂志,2012,30(6):462-463,480.
[4]钟世寿,李国苗,谭祥,等.两种铂类与吉西他滨联合用于初治老年晚期非小细胞肺癌患者临床对比观察[J].现代肿瘤医学,2015,23(15):2138-2141.
[5]李娜,韩子阳,郑斌,等.紫杉醇脂质体或吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床研究[J].中国临床药理学杂志,2014,30(12):1083-1085.
[6]姚德蛟.康莱特联合吉西他滨、顺铂治疗晚期非小细胞肺癌的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(15):1494-1496.
[7]周红兵,艾伟,孙林,等.紫杉醇脂质体和吉西他滨分别联合顺铂治疗晚期非小细胞肺癌的效果及其与中性粒细胞/淋巴细胞比值的相关性[J].中国医药,2015,10(4):468-472.
[8]Reaume MN,Leighl NB,Mittmann N,et al.Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer(Italian GEMVIN3/NCIC CTG BR14 trial)[J].Lung Cancer,2013,82(1):115-120.
[9]赵文英,陈冬云.伊立替康联合顺铂与吉西他滨联合顺铂一线治疗晚期非小细胞肺癌的随机对照研究[J].中华肿瘤杂志,2012,34(10):775-779.
[10]孙成晖,吴国强,严伟红,等.替吉奥和吉西他滨分别联合顺铂一线治疗EGFR野生型的晚期非小细胞肺癌的临床观察[J].中国医院药学杂志,2015,35(23):2129-2132.
[11]Kusagaya H,Inui N,Karayama M,et al.Biweekly combination therapy with gemcitabine and carboplatin compared with gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer:A randomized,phase-II study[J].Lung Cancer,2012,77(3):550-555.
[12]Zhang J,Gay HA,Russo S,et al.Phase Ⅱ study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer[J].Lung Cancer,2014,83(1):67-72.
[13]全吉钟,冯燕,王冬旭,等.吉西他滨联合洛铂或顺铂一线治疗老年晚期非小细胞肺癌患者的疗效[J].中国老年学杂志,2014,34(5):1181-1182.
[14]曾宗鼎,邢崇浩,覃世运,等.晚期非小细胞肺癌采用多西他塞联合顺铂治疗的疗效及安全性[J].实用癌症杂志,2015,30(5):762-764.
[15]刘倩.培美曲塞联合顺铂治疗晚期非小细胞肺癌患者的临床疗效及安全性[J].实用癌症杂志,2015,30(4):569-571.
